BiotechTube

CXA-101 + Ceftazidime

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Complicated Urinary Tract Infection

Conditions

Complicated Urinary Tract Infection

Trial Timeline

Jun 30, 2009 → Mar 11, 2010

NCT ID
NCT00921024

About CXA-101 + Ceftazidime

CXA-101 + Ceftazidime is a phase 2 stage product being developed by Merck for Complicated Urinary Tract Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT00921024. Target conditions include Complicated Urinary Tract Infection.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00921024Phase 2Completed

Competing Products

20 competing products in Complicated Urinary Tract Infection

See all competitors
ProductCompanyStageHype Score
ZY19489 + Ferroquine (FQ) + PlaceboZydus LifesciencesPhase 1
33
HRS-8427 + Imipenem and Cilastatin Sodium + HRS-8427 placebo + Imipenem and Cilastatin Sodium placeboJiangsu Hengrui MedicinePhase 3
77
HRS -8427 + Imipenem and Cilastatin SodiumJiangsu Hengrui MedicinePhase 2
52
Ceftolozane/Tazobactam + Metronidazole + Meropenem + PlaceboMerckPhase 3
77
Vancomycin + Daptomycin + Semi-Synthetic PenicillinMerckApproved
85
CXA-201 and metronidazole + MeropenemMerckPhase 3
77
Ceftolozane/Tazobactam + MeropenemMerckPhase 2
52
Imipenem+Cilastatin/RelebactamMerckPhase 3
77
Daptomycin + VancomycinMerckApproved
85
CXA-101/ tazobactam and metronidazole + meropenem plus saline placeboMerckPhase 2
52
CXA-201 + LevofloxacinMerckPhase 3
77
Ceftolozane/Tazobactam + Metronidazole + Meropenem + Placebo for MetronidazoleMerckPhase 2
52
MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazoleMerckApproved
85
MK0826, /Duration of Treatment : 8 Weeks + Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 WeeksMerckPhase 3
77
KLU156 + CoartemNovartisPhase 3
77
LYS228 + Standard of care therapyNovartisPhase 2
52
Artemether-lumefantrine (COA566)NovartisPhase 2/3
65
INE963NovartisPhase 2
52
KAE609 + SoC (Coartem) + KLU156NovartisPhase 2
52
KAF156 + Coartem + Lumefantrine Solid Dispersion FormulationNovartisPhase 2
52

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85